Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

计划入组 60 人 · 首次发布于 2026 年 1 月 12 日

SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation

计划入组 84 人 · 首次发布于 2010 年 1 月 22 日

Pharmacokinetics, Efficacy and Safety of the 304 Injection

计划入组 60 人 · 首次发布于 2019 年 6 月 10 日

BEAM-301

BEAM-302

BEAM-102

Beam Therapeutics

United States

EDWARD V. BEAM PHARMACY, INC.

United States

HYOGO ION BEAM MEDICAL CENTER

Japan

Beam Therapeutics Receives FDA Clearance for BEAM-304, a First-in-Class In Vivo Base Editing Therapy for Phenylketonuria

Beam Therapeutics Reports Breakthrough in Alpha-1 Antitrypsin Deficiency Treatment with BEAM-302 Base Editing Therapy

Beam Therapeutics Receives FDA Orphan Drug Designation for BEAM-101 Sickle Cell Disease Therapy